FDA Approves Unknown Drug — HIBROW HLTHCARE

# FDA Approves ANDA for Hibrow Healthcare Hibrow Healthcare received FDA approval for an abbreviated new drug application (ANDA207863) on February 4, 2019, expanding its generic drug portfolio and positioning the company to capture market share in an established therapeutic category. The approval enables Hibrow Healthcare to manufacture and distribute a generic alternative, potentially increasing competition and offering more affordable treatment options to patients in a competitive market segment.